InvestorsHub Logo
Followers 581
Posts 27164
Boards Moderated 1
Alias Born 03/18/2015

Re: None

Monday, 05/17/2021 10:38:26 PM

Monday, May 17, 2021 10:38:26 PM

Post# of 325
Wow. Im getting that special feeling guys. $10M:

"Over the last 12 months, we have been focused on building our intellectual property portfolio, which currently consists of 17 granted patent and patent applications, advancing the clinical development of our ketamine product pipeline targeting Parkinson's disease, depression and Lou Gehrig's disease, and developing novel microneedle patch delivery systems to unlock the clinical value of psychedelics to treat neuropsychiatric, neurodegenerative and pain disorders," said Fabio Chianelli, CEO of PharmaTher. "With the recent closing of the sale of our psilocybin program to Revive Therapeutics for up to CAD $10 million, of which we received $3 million in cash and $4 million in Revive common stock upfront, we are in a good financial position to advance our FDA Phase 2 clinical studies with ketamine and to finalize the development of our proprietary microneedle patch delivery systems for clinical trials and to partner with life sciences companies seeking a differentiated, safe and effective delivery option for psychedelics."

https://ih.advfn.com/stock-market/CNSX/PHRM/stock-news/84837117/pharmather-provides-update-on-psychedelic-product

Sometimes its Skil, Sometimes its Luc.

I’d rather have 1 genuine team follower then 100 look-a-likes.

Appreciate Member Marks!

ALL IMHO